Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc (BDRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bdrx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Biodexa Pharmaceuticals Plc (BDRX) measures how much investors pay for each dollar of the company's trailing earnings. BDRX's current PE ratio of N/A is calculated by dividing its stock price of $3.26 by its TTM earnings per share of -$141.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Biodexa Pharmaceuticals PlcYou BDRX | $1M | N/A | — | -$141.00 |
 BioVie Inc. BIVI | $13M | N/A | — | -$11.87 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 Estrella Immunopharma, Inc. ESLA | $49M | N/A | — | -$0.35 |
 Galmed Pharmaceuticals Ltd. GLMD | $3M | N/A | — | -$2.39 |
 Genprex, Inc. GNPX | $1M | N/A | — | -$17.40 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-113.82 | — | |
2024-12-31 FY2024 | — | $-92.47 | — | |
2023-12-31 FY2023 | — | $-228530.66 | — | |
2022-12-31 FY2022 | — | $-4943181.82 | — | |
2021-12-31 FY2021 | — | $-3525309.92 | — | |
2020-12-31 FY2020 | — | $-14326575.41 | — | |
2019-12-31 FY2019 | — | $-32557463.84 | — | |
2018-12-31 FY2018 | — | $-334775589.28 | — | |
2017-12-31 FY2017 | — | $-377946399.74 | — | |
2016-12-31 FY2016 | — | $-198934452.70 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Biodexa Pharmaceuticals Plc (BDRX) measures how much investors pay for each dollar of the company's trailing earnings. BDRX's current PE ratio of N/A is calculated by dividing its stock price of $3.26 by its TTM earnings per share of -$141.00.
Frequently asked questions
BDRX pe ratio · 6 questionsBDRX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.26 and TTM EPS of -$141.00. Data sourced from Financial Modeling Prep via BDRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biodexa Pharmaceuticals Plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08